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Summary: 
 
Thermal dose and absorbed radiation dose have been extensively investigated separately over the last 
decades. The combined effects of heat and ionizing radiation, such as thermal radiosensitization, have 
also been reported, but the individual modalities have not been compared with each other. In this paper, 
we propose a comparison of thermal and radiation dose by going back to basics and comparing the cell 
survival ratios. 
 
 
Abstract: 
 
Thermal dose and absorbed radiation dose have historically been difficult to compare because different 
biological mechanisms are at work. Thermal dose denatures proteins and the radiation dose causes 
DNA damage in order to achieve ablation. The purpose of this paper is to use the proportion of cell 
survival as a potential common unit by which to measure the biological effect of each procedure. 
Survival curves for both thermal and radiation doses have been extracted from previously published 
data for three different cell types. Fits of these curves were used to convert both thermal and radiation 
dose into the same quantified biological effect: fraction of surviving cells. They have also been used to 
generate and compare survival profiles from the only indication for which clinical data are available for 
both focused ultrasound (FUS) thermal ablation and radiation ablation: essential tremor thalamotomy. 
All cell types could be fitted with coefficients of determination greater than 0.992. As an illustration, 
survival profiles of clinical thalamotomies performed by radiosurgery and FUS are plotted on a same 
graph for the same metric: fraction of surviving cells. 
FUS and Gamma Knife have the potential to be used in combination to deliver a more effective 
treatment (for example FUS may be used to debulk the main tumor mass, and radiation to treat the 
surrounding tumor bed). In this case, a model which compares thermal and radiation treatments is 
valuable in order to adjust the dose between the two. 
Key words: ultrasound, thermal dose, radiation dose, damage index, High intensity focused ultrasound 
I. Introduction 
 
Therapies involving the use of ionizing radiation and/or thermal energy have a long history in 
the treatment of disease, including cancer. Evidence from an Egyptian papyryus suggests that 
as early as 3500 years ago heat was applied in an attempt to treat breast cancer(1, 2). Therapy 
involving radiation had to wait until the discovery of X-rays in 1895, however within several 
years of this discovery, radiation therapy based on radionuclides and low-energy X-ray 
generating equipment was used for the treatment of cancer. (3) More recently there have been 
parallel developments in the use of heat and ionizing radiation for both diffuse and focal 
disease, as well as attempts to combine the benefit of the two modalities. A number of 
techniques have been developed to allow the focal destruction of malignant tissue in humans, 
including ablation by radiofrequency (4), microwaves(5-12), lasers(13), magnetic 
nanoparticles(14, 15), and high-intensity focused ultrasound(16-18). Recent advancements in 
the focal treatment of cancer using ionizing radiation include the development of stereotractic 
radiosurgery (SRS)(19), stereotactic body radiotherapy (SBRT)(20-22), and intraoperative 
radiotherapy (IORT) (23, 24). 
 
From an early date and continuing to the present, investigation of the synergies between heat 
and ionizing radiation have been a natural avenue for research including the basic biology of 
hyperthermia(25), the most effective sequencing of heating and radiation(26, 27) , biological 
interactions between heat and radiation(28), and determination of thermal enhancement ratios 
and predictors of response(28-30). Significant evidence in the form of several randomized 
control trials exists to demonstrate that hyperthermia followed by radiation can significantly 
improve outcomes in head and neck cancer(31, 32), malignant melanoma(33), breast cancer 
(34), glioblastoma multiforme(35), pelvic tumors(36), cervical carcinoma(37), superficial 
tumors(38), cervical cancer(39), non-small-cell lung cancer(40), rectal cancer(41), among 
others(2, 42). The recent progress in focal ablative therapies such as HIFU and SRS/SBRT 
may also benefit from combined approaches. However, direct comparison of absorbed dose in 
ionizing radiation and thermal dose for heating have historically been difficult because of the 
widely different physical and biological mechanisms in play(1). 
In this work, we compare thermal and ionizing radiation modalities in terms of biological 
damage to tissue by using equivalent historical in-vitro cell survival data. By doing so, we aim 
to create a method for translation between measures of thermal and radiation dose. Essential 
tremor thalamotomy is currently the only indication for which quantitative clinical data are 
available for both radiation and FUS treatments. In order to illustrate this approach, we thus 
took into account the beam shaping capabilities of the stereotactic radiosurgery (SRS) and FUS 
devices available for treatment of essential tremor, in order to allow more direct comparison 
between FUS and SRS treatments. Our approach could facilitate dosimetry planning in the 
setting of combined radiosurgery and FUS. 
 
A. Biological effect of ionizing radiation and definition of radiation dose 
 
Photon-based ionizing radiation (X-rays and γ-rays) are indirectly ionizing; they deposit energy in 
tissue in a two-step process. In the first step, photolectric and Compton interactions between 
photons and atoms in tissue result in the transfer of energy to fast electrons ejected from the target 
atoms. In a second step, atoms in the targeted tissue are ionized as these fast electrons undergo 
Coulomb interactions with other atoms in the targeted tissue, transferring a fraction of their energy 
during each interaction(43). In traditional radiobiology theory, the biological target of ionizing 
radition is damage to DNA. In a minority of cases (~33%), DNA is directly ionized, leading to 
strand breaks. In the majority of cases (~66%), the ions created in irradiated tissue result in the 
creation of free radicals (most significantly hydroxyl radicals) which subsequently react with and 
create strand breaks in DNA. The ultimate biological effect of the DNA damage 
is mitotic death of the cells in the irradiated tissue(1). At higher, ablative doses there may 
additional biological mechanisms at play as well, including microvascular damage(44). 
Radiation dose is described in physical terms; the amount of energy absorbed per mass of 
tissue. This is the definition of “absorbed dose”, and is most commonly assigned units of Gray 
(Gy), where 1 Gy = 1 J/kg of energy absorbed in tissue (43). The amount of biological damage 
caused can be related directly to the physical quantity of absorbed dose, and this has become the 
standard method of prescribing the appropriate amount of radiation to be delivered in any given 
therapeutic setting. 
 
B. Biological effect of thermal energy and definition of thermal dose 
 
The response of cells to thermal insult at sub-ablative temperatures (such as temperatures 
employed in traditional hyperthermia) can be quite complex, involving the development of a 
combination of thermotolerance, cytotoxicity, and radiosensitization most likely mediated by 
protein denaturation within cells which increases proportionately to the thermal damage. Lower 
level of protein denaturation can trigger protective mechanisms such as increased expression of 
heat shock proteins which help to stabilize the cell against further thermal damage. Higher 
levels of protein denaturation can cause the inactivation of protein synthesis and DNA repair 
mechanisms resulting in cytotoxity and increased sensitivity to ionizing radiation. (45) When 
delivered at sufficient power to result in ablation, thermal energy ultimately results in 
coagulative necrosis(46). As with ionizing radiation, the extent of biological changes in tissue 
resulting from thermal exposure is correlated with the amount of energy absorbed in tissue. 
However, for thermal energy, it is the temperature to which the tissue is raised, and the duration 
of the heating that seem to play the predominent biological role. Sapareto and Dewey have 
defined a ‘thermal isoeffective dose’ (47). This has units of cumulative equivalent minutes at 
43°C (CEM 43°C), and allows conversion of any temperature/time (T/t) combination to the 
equivalent time for which the reference temperature of 43°C must be applied to obtain the same 
level of thermal damage: 
 
CEM43 = ∫t R43−T (t )dt 
 
0 
 
0.25 if T < 43°C 
R = 
 
The definition of the thermal isoeffective dose formalizes the idea that two different 
temperatures applied over different time intervals can have the same biological effect in a given 
tissue. 
 
C. Cell survival curves 
 
Traditionally, the most common method for assessing cell survival in thermo- and radiobiology 
uses survival curves. The principle of survival curve analysis is the same, irrespective of the 
source of cell damage. The curve depicts the relationship between the damage to which a cell 
has been subjected and the cell’s subsequent ability to divide to form a colony. . For the studies 
considered here, in vitro assays have been used as the source data. The development of survival 
curves involve plating a known number of cells (determined using a standard counting method) 
out into tissue culture dishes following exposure to heat or ionizing radiation, and analyzing 
their response at a later time point. The surviving fraction is calculated by normalizing the 
number of cells or colonies seen in treated samples to that seen in controls. This is then plotted 
on a logarithmic scale against the thermal or radiation dose delivered.(1) A minimum colony 
size (usually 50 cells) is used as a cutoff for minimal critical mass of cells to survive as a 
colony. It should be noted, that while this type of assay is frequently assumed to measure 
individual cell survival directly, the reduction in number after treatment may also be due in part 
to cells going into a “dormant” state, and not dividing. (1)Typical survival curves are shown in 
Figure 1 for radiotherapy and thermal doses. For thermal treatments, the cells were subjected to 
a variety of temperatures as shown in the figure legend. However, when both temperature and 
time are taken into account by calculating thermal dose in CEM, the data fall along a common 
curve. 
 
II. Materials and methods 
 
 
A. Literature Review 
 
An extensive review of the literature was conducted to identify studies reporting cell survival 
for thermal exposure, with the goal of identifying cell subtypes for which there were matching 
published reports on cell survival for ionizing radiation. Basically a literature review for both 
thermal and radiation cell survival was performed and then data were cross referenced. The 
literature review was conduced using Cornell University’s online library during June and July 
of 2013. Key words used in this literature review included: cell survival, radiation treatment, 
thermal treatment, thermal dose, radiation dose, tissue damage, and hyperthermia. Some 
exclusion criteria included: articles not written in English, studies that only used thermal and 
radiation treatment in combination, and studies that did not measure cell survival. Table 1 lists 
the publications selected for thermal and ionizing radiation modalities. The list is not exhaustive 
and the literature search was stopped when three different cell-types were found for which 
survival data was available: Chinese hamster ovary cells (CHO), Chinese hamster lung cells 
(CHL), and human glioblastoma tumor cells will thus be used in the rest of the article to 
illustrate our approach. 
 
B. Data Extraction and Cell Survival Modeling 
 
Each point of the survival data, as displayed in the reports selected for thermal and ionizing 
radiation experiments, was manually transferred into Matlab version R2013a (Mathworks, Inc., 
Natick, MA) for each cell type: Chinese Hamster Ovary (CHO), Chinese Hamster Lung (CHL), 
and Human Glioblastoma Astrocytoma (GBA). The radiation dose survival profiles for each of 
the 3 cell types were modeled using the Universal Survival Curve (USC) developed by Park, et 
al(48). The USC is one of several derivatives of the linear quadratic model that attempt to take 
into account low and high doses survival regimes (44, 49-53): 
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where S is the cell survival, defined as the ratio between the remaining number of undamaged 
cells at time t indicated by N(t) to the number of undamaged cells N(0) present prior to the start 
of the treatment, Dr is the radiation dose in Gray, n is the number of fractionations, and α (units 
of loge of the cells killed per Gy) and β (units loge of cells killed per Gy
2
) are constants that 
describe the linear and quadratic portions of the curve, respectively. DT is the transition dose, 
where the curve changes from using the low dose model to the high dose. Do is a measure of the 
slope of the linear portion of the curve at high doses and Dq is the x-intercept of the survival 
line valid for ≤ . β and DT are calculated from the parameters α , Do, and Dq to ensure continuity 
and differentiability at DT (48): 
= (1−    ∗     )2  
4     ∗     
 = 
2∗     
1−    ∗     
  
 
In traditional radiobiology, the α and β terms above are also often represented in ratio form (the 
α/β ratio, units of Gy), which is the dose at which the linear and quadratic components are 
equal. Tumors and tissue which show an early response to radiation damage tend to have a 
large α/β ratio, while tissue which shows a late response to radiation damage have a small α/β 
ratio)(1, 53, 54). Thermal dose survival data were fitted with a linear-quadratic equation for all 
3 cell types (55, 56)): 
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−(    +         2) 
  
 
where S is the cell survival, Dt is the thermal dose in equivalent minutes, and a and b are 
constants. 
 
Damage index Ω is widely used for RF and laser ablation. It is the logarithm of the ratio 
between the number of undamaged cells N(0) present prior to the start of the treatment to the 
remaining number of undamaged cells at time t indicated by N(t) (57): 
Ω = ln 
(0) 
= ln 
1 
( )     
 
Ω can thus be expressed as a function of the thermal dose with the same fit coefficients a and b 
calculated above: 
Ω = + 2 
 
 
D. Evaluation of clinical treatment spot sizes 
 
For sake of illustration, clinical data from both radiation surgery and thermal ablation have been 
processed. The only indication which the authors could get access to data sets for both is es-
sential tremor. Thalamotomy data for both FUS and SRS were thus analyzed for predicted cell 
survival. The clinical data used for analysis is anonymized data from a pilot study for essential 
tremor patients conducted at the University of Virginia(58) under oversight and approval of the 
university’s institutional review board (IRB). The anonymized Gamma Knife SRS dose distri-
butions for the 3 cases used in the analysis have been determined by the IRB to be not subject 
to IRB review. 
 
 
 
1. Focused Ultrasound 
 
The clinical FUS study consisted of 15 patients with essential tremor whose condition did not 
improve with medication. The patients were treated with MR-guided FUS, targeting the ventral 
intermediate (VIM) nucleus of the thalamus. A series of low-power sonications were delivered 
to the intended target to validate the geometric accuracy of the setup. 
 
Temperature maps were recorded during treatment using MR thermometry(59). In this 
study, the temperature for each voxel was read from the raw data files for each timepoint of the 
sonication and used to calculate the thermal dose. The thermal dose profile was determined by 
normalizing the data to the maximum thermal dose in the volume of interest. 
Using the calculated thermal profiles and the cell survival-thermal dose relationship for 
all cell lines (CHO, CHL and GBA), cell survival was calculated for each voxel in the region of 
interest. 
 
2. Gamma Knife Radiosurgery 
 
The clinical radiosurgery data is derived from treatment plans for 3 radiosurgical thala-
motomies performed on the Gamma Knife at University of Virginia for individuals with essen-
tial tremor that have failed to improve with other treatments and are unwilling, or unable, to un-
dergo an invasive procedure. Radiosurgical thalamotomy was achieved using the Leksell Gam-
ma Knife to deliver a maximum dose of 130-140Gy with a 4mm isocenter to the VIM nucleus 
on the opposite side of the brain from the more severe tremor. The technique employed at the 
University of Virginia is similar to techniques published in the literature. (60) 
SRS dose distributions were created using the Gamma Knife treatment planning 
software (Leksell GammaPlan versions 8.0 - 10.1, Elekta AB, Stockholm). The resulting dose 
distributions were exported in anonymized DICOM-RT format. The radiotherapy dose profiles 
in x and y directions were averaged and then normalized to the maximum administered dose 
and converted to a percentage. Using the cell survival-radiotherapy dose relationship for CHO, 
CHL and GBA, the fraction of cells surviving was determined as a function of distance. 
 
 
III. Results 
1. Cell survival fitting 
 
The resulting cell survival curves, extracted from previous studies, (61-66) are shown in Figure 2 for 
radiotherapy and thermal dose. 
 
Results are summarized in Table 2. The α/β values for the radiation treatment on the 3 types of cells are 
close to previously published values.(54, 67, 68). The linear quadratic fit of the curves resulted in an 
average coefficient of determination of R
2
=0.995 , a maximum of 0.998, and a minimum of 0.992. All 
R
2
 values are displayed in Table 2. In order to achieve a cell survival fraction of 10
-5
 (i.e. a survival of 
0.001%), a radiotherapy dose of 17Gy must be applied to CHO cells, 20.5Gy to CHL cells, and 14Gy 
to GBA cells. To achieve the same percentage of surviving cells a thermal dose of 148.5CEM must be 
administered to the targeted CHO cells, 178CEM to CHL cells, and 249.5CEM to GBA cells. 
 
2. Estimated cell survival from clinical MRgFUS and Gamma Knife essential 
tremor treatments 
 
The dose profiles from the clinical essential tremor data for FUS and SRS are shown in Figure 3A, 
normalized to the point of maximum delivered dose (3160 CEM for thermal and 130 Gy for SRS). 10% 
of the maximum dose is delivered to cells at 1.6mm for thermal dose and at 6.9mm for radiotherapy 
exposures. As seen in the simulated profiles, the thermal dose profile drop off is sharp and by 3mm the 
dose is at zero. For the radiotherapy dose, the drop off is much more gradual and reaches an average of 
4% of the maximum dose at 11 mm. 
 
The corresponding simulated cell survival curves for the essential tremor clinical data are displayed in 
Figure 3B. As an example, for GBA cells, the survival curve for the radiotherapy dose clinical data 
reaches a level of 90% at 28.9mm and 99.5% at 27.78mm. For the thermal dose, 90% survival occurs 
at a distance of 3.71mm and reaches 99.5% survival at a distance of 6.5mm. The survival curve for 
radiotherapy dose drops off more gradually than the thermal dose survival curve (Figure 3A). 
IV. Discussion 
 
Potential clinical applications of FUS overlap significantly with SRS. FUS is being considered as a 
substitute modality for radiotherapy for indications such as essential tremor, neuropathic pain, and 
others. However, the techniques do not need to compete. A more common scenario may be to use FUS 
in combination with radiotherapy, especially in the treatment of malignant disease. In this setting, FUS 
may be used to debulk the main tumor mass, allowing for significant and immediate symptomatic 
relief. This may be followed by radiation to the surrounding tumor bed with the goal of reducing local 
failure and regional recurrences. Investigators are also looking at the reverse approach, where the 
tumor and the surrounding tumor bed are first irradiated to damage the ability of the cells to reproduce. 
This is then followed by FUS to debulk the main tumor. 
In either situation, a method of quantifying the biological damage inflicted on both normal and 
diseased tissue from both modalities, like the one introduced in this paper, would be valuable, and in 
particular for areas of tissue receiving sub-lethal doses from either modality on its own. 
Historically, creating a direct comparison between thermal dose and radiation dose has been 
considered impractical (1). This is in part because the concept of absorbed dose for ionizing radiation 
describes the physics of the situation; i.e. the energy absorbed by a mass of tissue from exposure to 
ionizing radiation (43). Conversely, the formulation of the thermal iso-effective dose, is based on 
empirically observed effects in heated cells. 
However, SRS (19) and FUS surgery (16, 69) attempt to achieve a similar biological effect: the 
ablation of a volume of tissue. SRS, especially when delivered in a single fraction, delivers a dose to 
tissue that can be considered “ablative” in the sense that the expected surviving fraction of cells is low 
(70). Likewise, FUS achieves ablation of a desired region of tissue by heating to a thermal isoeffect 
dose known to cause coagulative necrosis with a similarly negligible surviving cell fraction (71, 72). 
A threshold for damage of 240CEM was determined in vivo in dog prostate(73) and in muscle(74) and 
corresponds to the threshold used in most clinical systems(75). Normalization to a similar biological 
endpoint makes feasible a direct comparison of radiation dose and thermal isoeffect. The threshold 
thermal or radiation dose required to “just” achieve ablation gives us a sort of “calibration” point in 
the spectrum of biological damage at which to equate the two dose formulations. 
Equating the dose fomulations might benefit the planning of combination therapies which take 
advantage of the synergistic effect of radiotherapy and thermal ablation. Compared to RF ablation 
alone, RF ablation combined with radiation therapy has been shown to increase the ablation volume in 
rat tumors(76) and improve survival(77), has shown a low rate of complications in patients with 
unresectable lung cancer(78-80) and has increased the relapse-free survival rate in prostate 
adenocarcinoma (81). This pioneering work could be revisited in an optimal way by taking advantage 
of the non invasive and conformal treatment capabilities of focused ultrasound and external beam 
therapy for inducing thermal and radiation effects with 3D planning based on the cell survival 
formulation proposed here. 
The thermal energy resulting in cytotoxicity drops off faster than for radiation therapy (Fig. 3). In part, this 
is related to the physics and technical details of the devices. Gamma Knife, used as a platform for the 
radiosurgery dose distibutions in our study, achieves a steep dose profile through the application of a large 
number (192 in the Perfexion model Gamma Knife used in this study) cross-firing beams that are 
collimated so they intersect with high precision at a focal point. A single irradiation location, or 
“isocenter” creates an approximately spherical dose distribution. Irradiation of irregularly shaped targets is 
achieved by using multiple isocenters and collimator settings at different positions. The dose falloff on a 
Gamma Knife is fundamentally dependent on the attenuation of each beam (which is at 60Co energy), the 
penumbra of each beam, and the total number of beams, and the isodose level in the distribution placed at 
the treatment margin of the target(82). The sharper spatial distribution falloff of the thermal dose is linked 
to the size of each individual heated region (focal spot) and thus to the ultrasonic transducer geometry, and 
the frequency used. This is not unexpected as thermal conduction 
is a very inefficient method of heating tissue(83): thermal conduction is an inherent limitation for 
large treatment volumes with focused ultrasound as the focal spot is small. The whole volume needs 
to be treated spot by spot. Nevertheless, limited diffusion can also be seen as an advantage as it 
contributes to a sharper boundary and a better control of energy deposition. 
 
A. Limitations of this study 
 
The intent of this paper was to explore the potential utility of equating thermal dose and radiation dose 
effects using cell survival as a common unit of measurement. As there is limited data collected with 
the intent of making such a direct comparison, there are assumptions that impact the uncertainties in 
the analysis including the in-vitro cell survival data used in the study, the the accuracy of survival 
models at ablative doses, and simplification of the possible complexities of the joint biological effects 
of thermal energy and ionizing radiation. 
 
Limitations of in-vitro cell survival data in this study 
 
Perhaps the most significant limitation of our experiment is that in-vitro studies do not represent 
clinical reality. By design, in-vitro experiments use cells grown under carefully controlled conditions. 
The in-vivo situation is obviously much more complex; for example our models do not take into 
account the heat sink effect of the surrounding tissue vasculature (84), cell-cycle differences (85), or 
tissue inhomogenities which can distort thermal and radiation dose (86-88). Stochastic models have 
shown that time-temperature history, tumor geometry, tumor perfusion, and uniformity of heating are 
all likely to affect cell survival rates(89). Nor do in-vitro models account for immunological effects, 
inflammatory effects, chemokines, or cytokines that are present in-vivo. (90, 91)In addition, the cell 
lines used to create the thermal dose and radiation dose survival curves in this paper do not correspond 
with the cell types (i.e. normal brain tissue) irradiated during a FUS thalamotomy or radiosurgery 
thalamotomy. This was because of the non-existence of published data for our chosen clinical example. 
The mismatch between in-vitro cell lines and the cells found in human brain tissue creates 
uncertainties on the specific parameters determined for our model fit. As in-vitro and in-vivo cell 
survival data is accrued for thermal and radiation doses over a larger range of cell-types, the 
method presented in this paper can be refined to include better parameter estimates. 
 
Limitations of survival models at ablative doses 
 
Another limitation to our approach is that the mathematical models used for thermal and radiation 
dose derive from in-vitro cell survival data acquired at sub-ablative doses. Both the thermal dose and 
ionizing radiation cell survival models have been shown to have weaknesses at high, single-fraction 
doses. Ideally, experiments should be conducted on the same types of cells, with the same cell survival 
assay and for SRS-like doses. Multiple models for thermal damage and radiation damage could also be 
employed to better represent the likely uncertainty in the calculations(92). This is beyond the scope of 
the present paper. 
 
Simplifying assumptions regarding the joint biological effects of thermal energy and 
ionizing radiation 
 
A simplifying assumption of the study is that thermal dose and radiation dose may be treated 
independently. In practice, there is likely some degree of interaction between the two. For instance, 
hyperthermia studies have demonstrated in-vitro that the achievable radiosensitization caused by 
heating is dependent on the sequence and time interval between heating and irradiation. While data 
remains inconclusive, there is a consensus that simultaneous heating and irradiation would 
maximize the dose enhancement effect due to heat, and as the interval between heat and radiation 
increases (regardless of sequence) the degree of enhancement decreases(26). Radiosensitization may 
also be enhanced through heating by preferentially killing chronically hypoxic tissue as is often 
found in the center of malignant tumors as they grow. These hypoxic regions tend to be 
radioresistant, and it is unclear how using heat to destroy these regions would effect the overall 
sensitivity profile to a joint treatment. A related effect is that heating can cause increased perfusion 
to targeted tissue, helping to reoxygenate (and thus radiosensitize) hypoxic areas of tissue(93, 94). 
This study attempts to relate thermal dose and radiation dose at a very low “ablative” level of cell kill, 
perhaps avoiding some of the complexities of the interactions between the biology of thermal and 
radiation insults. The thermal dose profiles presented in the results include a thin region of sub-lethally 
heated tissue. This tissue likely benefits from some of the radiosensitization that has been 
demonstrated from these earlier hyperthermia results, and this is not accounted for in our model. 
However further investigation will be required to understand what, if any, clinical significance these 
sub-lethally heated regions would have on the ultimate outcome of a joint thermal/radiation treatment 
and how it might affect thermal or radiation dose prescriptions. 
 
B. Other Limitations of the work 
 
Finally, different tissue and organ types have differential sensitivity to both ionizing and thermal dose. 
This is also not modeled in the current approach, however it is inherent in the in-vitro cell data used in 
the study. Differential response to ionizing radiation is partly related to the length of the cell-cycle of a 
given cell type, as lethal DNA damage is manifested during mitosis. Cells with short lifespans tend to 
show early reaction to radiation insult. Slower-dividing cells tend to show later reactions.(1) The 
primary mechanism of thermal cell death is a combination of protein denaturation and coagulative 
necrosis. This could reasonably be assumed to be similar across all cell lines. The differences then 
may be due to alternative mechanism of cell death such as disruption of intracellular signal 
transduction and cell motility(42, 95, 96) 
 
 
V. Conclusion: 
 
Radiation- and thermal- based treatments are difficult to compare because of the differences in the 
physics of the energy deposition and the resulting biological effects . The work presented in this paper 
is a first attempt at creating a method of equating thermal and radiation doses for ablative treatments by 
considering “ablation” as a common biological endpoint. It was shown how radiation dose and thermal 
dose could both be expressed in terms of percentage of surviving cells, and thus be compared with the 
same quantitative effect on tissues. Much work remains to be done in order to validate the regression 
equations and dose models against both in-vitro and in-vivo targets of different heterogeneous tissues. 
IV. Figures and Tables 
 
 
 
 
FIGURE 1. Figure 1: An example of a survival curve for radiotherapy exposure (A), extracted 
from (97), and for heated cells (B), extracted from previously published results (98), with thermal 
isoeffective dose calculated from the combination of heating duration and temperature 
 
 
 
FIGURE 2. Fraction of cells surviving as a function of the radiation (A) or thermal (B) dose for (●) 
CHO, (♦) CHL, and (■) GBA. Data have been extracted from previously published results: 
(CHO),(61) (CHL),(62) (GBA)(65) (A) and (CHO),(63) (CHL),(66) (GBA)(64) (B). 
 
 
 
 
 
 
 
 
FIGURE 3. Average dose profiles (A) and corresponding survival curves (B) for essential tremor 
clinical data. The average profiles amongst patients are shown in four directions from the center and 
the average is highlighted in bold (A) . Survival curves for essential tremor clinical data for FUS (solid) 
and SRS (dashed) are plotted for each cell type available. 
 
 
Reference Article Type of Tissue Investigated 
Treatment 
Modality 
Dose 
Range 
Sensitivity of Human Cells to Mild Hyperthermia [24] 
Human Glioblastoma Tumor 
Cells 
U87MG Heat 
0-240 
CEM 
Thermal Dose Determination in Cancer Therapy [21] Chinese Hamster Ovary 
 
Heat 
0-150 
CEM 
Cellular Effects of Hyperthermia: Relevance to the minimum dose for thermal 
damage[25] 
Chinese Hamster Lung V79 Heat 
0-150 
CEM 
Arrhenius Relationships from the Molecule and Cell to the Clinic[26] Chinese Hamster Ovary 
 
Heat 
0-150 
CEM 
Basic Principles of thermal dosimetry and thermal threshold for tissue damage from 
hyperthermia [27] 
Chinese Hamster Ovary 
 
Heat 
0-180 
CEM 
A Transient Thermotolerant Survival Response Produced by Single Thermal Doses in 
HeLa Cells [28] 
HeLa 
 
Heat 
0-480 
CEM 
Differential Effect of Hyperthermia on Murine Bone Marrow Normal Colony-forming 
Units and AKR and L1210 Leukemia Stem Cells [29] 
Leukemia Cells L1210, AKR Heat 
0-60 
CEM 
A Comparison of Cell Killing by Heat and/or X Rays in Chinese Hamster V79 Cells, 
Friend Erythroleukemia Mouse Cells, and Human Thymocyte MOLT-4 [30] 
Chinese Hamster Lung V79 Radiation 0-16 Gy 
Cellular Responses to Combinations of Hyperthermia and Radiation [31] Chinese Hamster Ovary 
 
Radiation 0-11 Gy 
Cross-Resistance to Ionizing Radiation in a Murine Leukemic Cell Line Resistant to 
cis-Dichlorodiammineplatinum(II): Role of Ku Autoantigen [32] 
Leukemia Cells L1210 Radiation 0-10 Gy 
Effect of Hyperthermia on the Radiation Response of two Mammalian Cell Lines [33] 
Chinese Hamster Ovary , 
mouse mammary sarcoma 
HA-1, EMT-
6 
Radiation 0-12 Gy 
Effects of propranolol in combination with radiation on apoptosis and survival of 
gastric cancer cells in vitro [34] 
Human gastric 
adenocarcinoma cells 
BGC-823, 
SGC-7901 
Radiation 0-10 Gy 
Enhancement of Radiation Damage in Cellular DNA Following Unifilar Substitution 
with Iododeoxyuridine [35] 
Chinese Hamster Lung V79 Radiation 0-16 Gy 
Hyperthermia Radiosensitization in Human Glioma Cells Comparison of Recovery of 
Polymerase Activity, Survival, and Potentially Lethal Damage Repair [36] 
Human Glioblastoma Tumor 
Cells 
U87MG Radiation 0-12 Gy 
Influence of Hyperthermia on Gamma-Ray-Induced Mutation in V79 Cells [37] Chinese Hamster Lung V79 Radiation 0-12 Gy 
Interaction of Hyperthermia and Radiation in CHO Cells: Recovery Kinetics [38] Chinese Hamster Ovary 
 
Radiation 0-12 Gy 
Long duration mild temperature hyperthermia and brachytherapy [39] 
Human Normal fibroblasts, 
Human radiation resistant 
melanoma cells, Human 
Ovarian Carcinoma cells 
AG1522, 
SkMe13, 
A2780 
Radiation 0-10 Gy 
  
TABLE 1. Review of papers reporting survival of cells exposed to thermal rise or ionizing radiations, 
matched for cell subtype and dose range. 
 
 
 
 
 
 
 
USC fit (radiation dose)  α (1/Gy) β (1/Gy2) α/β 
(Gy) 
Dq 
(Gy) 
Do 
(Gy) 
DT 
(Gy) 
R
2
 
CHO 0.043 0.062 0.69 2.93 1.23 6.19 0.993 
CHL 0.11 0.026 4.12 5.23 1.33 12.22 0.995 
GBA 0.14 0.094 1.53 1.81 1.06 4.28 0.996 
Exponential fit (thermal dose) a (1/CEM) b (1/CEM
2
) a/b (CEM) R
2
 
CHO 0.0047 0.00049 9.6 0.994 
CHL 0.035 0.00017 210 0.992 
GBA 0.044 9.1e-6  4800 0.998 
 
 
TABLE 2. Parameters for the Universal Survival Curve (USC) for radiation therapy doses and linear 
quadratic exponential fit for thermal doses. 
Moderate Hyperthermia and Low Dose Irradiation [22] Chinese Hamster Lung V79 Radiation 0-14 Gy 
Radiosensitivity and Capacity to Recover from Radiation Induced Damage in 
Pimonisazol-Unlabeled Intratumor Quiescent Cells Depend on p53 Status [40] 
Human head and neck 
squamous carcinoma cells 
SAS Radiation 0-14 Gy 
Recovery of Sublethal Radiation Damage and is inhibition by Hyperthermia in normal 
and transformed mouse cells [41] 
Chinese Hamster Lung V79 Radiation 0-14 Gy 
The p65 subunit of nuclear factor-κB is a molecular target for radiation sensitization of 
human squamous carcinoma cells [42] 
Human head and neck 
squamous carcinoma cells 
SCC-35, d6, 
d12 
Radiation 0-11 Gy 
Thermal radiosensitization in Chinese hamster and mouse C3H 10T 1/2 cells. The 
thermotolerance effect [40] 
Chinese Hamster Lung, mouse 
embryo 
V79, C3H Radiation 0-14 Gy 
Thermal Sensitivity and Radiosensitization in V79 Cells after BrdUrd or IdUrd 
Incorporation [43] 
Chinese Hamster Lung V79 Radiation 0-16 Gy 
Thermally Enhanced Radioresponse of Cultured Chinese Hamster Cells: Inhibition of 
Repair of Sublethal Damage and Enhancement of Lethal Damage [44] 
Chinese hamster fibroblasts V79 Radiation 0-11 Gy 
Thermal sensitivity and radiosensitization in Chinese hamster V79 cells exposed to 2-
aminopurine or 6-thioguanine [45] 
Chinese Hamster Lung V79 Radiation 0-14 Gy 
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